title: The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan.
abstract: BACKGROUND
  There are little data about adverse effects and immunogenicity of flu vaccine in Asian pregnant women.
  
  
  METHODS
  This prospective trial (NCT01514708) enrolled 46 pregnant women who received a single intramuscular dose of trivalent flu vaccine (AdimFlu-S®) containing 15 mcg of hemagglutinin for each strain/0.5 mL from influenza A (H1N1), influenza A (H3N2), and influenza B after the first trimester. Blood samples were collected at day 0 and 28 after vaccination, and at delivery. Cord blood was also collected. Hemagglutination inhibition (HAI) assays were performed to determine seroprotection and seroconversion rates and fold increase in the HAI geometric mean titer (GMT).
  
  
  RESULTS
  Twenty-eight days after vaccination the seroprotection rate against H1N1, H3N2, and influenza B was 91.3%, 84.8% and 56.5%, respectively. The GMT fold increase was 12.8, 8.4, and 4.6 for H1N1, H3N2, and influenza B, respectively. At delivery, both the seroprotection rate (86.4%, 68.2%, and 47.7%) and GMT fold increase (9.4, 5.7 and 3.8) were slightly lower than day 28. The seroprotection rate and GMT fold increase in maternal and cord blood samples were comparable. No significant adverse effects were detected.
  
  
  CONCLUSIONS
  Trivalent flu vaccine induces a strong immune response in pregnant women and their infants without adverse effects.
  
  
  BACKGROUND
  Clinical Trials. gov NCT01514708.
authors.affiliation: Department of Obstetrics and Gynecology, National Taiwan University Hospital, Hsin Chu branch, Hsin Chu, Taiwan.
authors.forename: Shin-Yu
authors.initials: SY
authors.lastname: Lin
authors.forename: En-Tzu
authors.initials: ET
authors.lastname: Wu
authors.forename: Chia-Hui
authors.initials: CH
authors.lastname: Lin
authors.forename: Ming-Kwang
authors.initials: MK
authors.lastname: Shyu
authors.forename: Chien-Nan
authors.initials: CN
authors.lastname: Lee
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D056738:Cross Protection; D005260:Female; D005312:Fetal Blood / Q000276:immunology* / Q000821:virology; D006385:Hemagglutination Inhibition Tests; D006389:Hemagglutinins, Viral / Q000235:genetics / Q000276:immunology; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D007273:Injections, Intramuscular; D011247:Pregnancy; D011446:Prospective Studies; D013624:Taiwan; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines